MediWound Ltd.
MDWD · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | -0.02 | 0.17 | -0.27 | -0.10 |
| FCF Yield | -11.22% | -18.47% | -18.49% | -14.63% |
| EV / EBITDA | -6.23 | -17.61 | -1.89 | -4.80 |
| Quality | ||||
| ROIC | -41.03% | -28.26% | -22.07% | -124.61% |
| Gross Margin | 13.03% | 19.15% | 49.69% | 36.91% |
| Cash Conversion Ratio | 0.45 | 1.56 | 0.61 | 0.66 |
| Growth | ||||
| Revenue 3-Year CAGR | -8.61% | -7.70% | 6.78% | -9.24% |
| Free Cash Flow Growth | -17.53% | -36.09% | -32.27% | -20.30% |
| Safety | ||||
| Net Debt / EBITDA | 0.08 | 1.13 | 1.83 | 0.85 |
| Interest Coverage | -25.80 | -45.64 | -51.51 | -67.19 |
| Efficiency | ||||
| Inventory Turnover | 6.53 | 5.31 | 6.79 | 12.49 |
| Cash Conversion Cycle | 76.49 | 53.05 | 32.44 | -50.22 |